Development
Alnylam Pharmaceuticals, Inc.
ALNY
$300.83
-$7.17-2.33%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 61.08% | 56.87% | -8.44% | -19.27% | -32.64% |
| Total Depreciation and Amortization | 13.42% | 19.27% | 12.25% | 6.05% | -4.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -19.13% | -26.66% | 46.22% | 52.85% | 89.93% |
| Change in Net Operating Assets | 130.26% | 73.75% | 27.38% | 36.31% | 78.16% |
| Cash from Operations | 119.24% | 100.35% | 18.24% | 7.05% | 15.65% |
| Capital Expenditure | 13.67% | 5.22% | 16.99% | 11.63% | 5.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -213.56% | -424.88% | 136.99% | 174.37% | 222.59% |
| Cash from Investing | -298.61% | -126.24% | 117.59% | 148.89% | 161.97% |
| Total Debt Issued | -- | -100.06% | 306.44% | 103.22% | 103.22% |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | -43.14% | -30.04% | 80.48% | 21.29% | 5.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -20.43% | 14.86% | -95.46% | -94.61% | -93.81% |
| Cash from Financing | -59.57% | -70.01% | -50.59% | -64.48% | -65.86% |
| Foreign Exchange rate Adjustments | 186.02% | 76.14% | 132.96% | 58.94% | 17.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -215.66% | -90.70% | 148.28% | -10.44% | -85.64% |